MCB-613 exploits a collateral sensitivity in drug resistant <i>EGFR</i> -mutant non-small cell lung cancer through covalent inhibition of KEAP1Christopher F. Bassil, Kris C. Wood, Kévin Jubien-Girard et al.|bioRxiv (Cold Spring Harbor Laboratory)|2023Cited by 0